Published in Cell Chromosome on May 24, 2004
Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Inf Model (2008) 0.98
A novel DNA intercalator, butylamino-pyrimido[4',5':4,5]selenolo(2,3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells. Invest New Drugs (2009) 0.90
Synthetic and biosynthetic studies on FR900482 and mitomycin C: an efficient and stereoselective hydroxymethylation of an advanced benzazocane intermediate. Org Lett (2007) 0.89
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence. J Biol Inorg Chem (2011) 0.77
Harnessing of Programmed Necrosis for Fighting against Cancers. Biomol Ther (Seoul) (2014) 0.76
Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065. Toxins (Basel) (2009) 0.76
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
CpG islands in vertebrate genomes. J Mol Biol (1987) 23.16
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
A DNA damage checkpoint response in telomere-initiated senescence. Nature (2003) 12.55
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A (2002) 9.60
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Histone and chromatin cross-talk. Curr Opin Cell Biol (2003) 8.69
Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell (2003) 7.48
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev (2000) 7.29
Heterochromatin and epigenetic control of gene expression. Science (2003) 7.12
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem (1999) 6.14
Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science (1988) 5.97
Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol (2001) 5.81
ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature (2000) 5.55
The many substrates and functions of ATM. Nat Rev Mol Cell Biol (2000) 5.46
DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer (2002) 4.69
Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material. Prog Biophys Mol Biol (1986) 4.62
Structure and mechanism of DNA topoisomerase II. Nature (1996) 4.56
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
DNA tetraplex formation in the control region of c-myc. Nucleic Acids Res (1998) 4.09
A tetrameric DNA structure with protonated cytosine.cytosine base pairs. Nature (1993) 4.03
CpG islands and genes. Curr Opin Genet Dev (1995) 3.83
Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol (2003) 3.80
Gametic imprinting in mammals. Science (1995) 3.49
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science (1999) 3.47
Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods (2002) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res (1988) 3.26
Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci U S A (1991) 3.14
Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci (2003) 3.05
Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods (2002) 2.99
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
Common themes in mechanisms of gene silencing. Mol Cell (2001) 2.88
Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science (1992) 2.79
CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68
Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem (1997) 2.66
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med (2001) 2.60
HMGB proteins and gene expression. Curr Opin Genet Dev (2003) 2.55
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J (1984) 2.55
P53 and radiation responses. Oncogene (2003) 2.52
Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep (2003) 2.49
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta (2001) 2.30
Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci U S A (1988) 2.29
The crystal structure of a parallel-stranded guanine tetraplex at 0.95 A resolution. J Mol Biol (1997) 2.25
Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry (1996) 2.17
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A (1994) 2.12
Mitotic DNA damage and replication checkpoints in yeast. Curr Opin Cell Biol (1998) 2.11
DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene (2003) 2.10
The Holliday junction in an inverted repeat DNA sequence: sequence effects on the structure of four-way junctions. Proc Natl Acad Sci U S A (2000) 2.09
Anticancer therapy targeting the apoptotic pathway. Lancet Oncol (2003) 2.06
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med (2001) 2.04
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev (2003) 1.95
G-quadruplex DNA: a potential target for anti-cancer drug design. Trends Pharmacol Sci (2000) 1.94
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003) 1.92
Selective interactions of cationic porphyrins with G-quadruplex structures. J Am Chem Soc (2001) 1.91
HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans (2001) 1.84
DNA sequence preferences of several AT-selective minor groove binding ligands. Nucleic Acids Res (1995) 1.82
Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol (2003) 1.81
Molecular recognition of B-DNA by Hoechst 33258. Nucleic Acids Res (1985) 1.80
Structure and function of "metalloantibiotics". Med Res Rev (2003) 1.74
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry (1996) 1.73
Reactivating the expression of methylation silenced genes in human cancer. Oncogene (2002) 1.73
Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev (1998) 1.72
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Distamycin and penta-N-methylpyrrolecarboxamide binding sites on native DNA. A comparison of methidiumpropyl-EDTA-Fe(II) footprinting and DNA affinity cleaving. J Biomol Struct Dyn (1984) 1.66
G-quadruplexes as targets for drug design. Pharmacol Ther (2000) 1.63
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther (2003) 1.61
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica (2002) 1.60
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58
Secondary DNA structures as molecular targets for cancer therapeutics. Biochem Soc Trans (2001) 1.56
A nuclease hypersensitive element in the human c-myc promoter adopts several distinct i-tetraplex structures. Biochem Biophys Res Commun (2000) 1.52
Epigenetic targets in hematopoietic malignancies. Oncogene (2003) 1.51
An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem J (2003) 1.48
Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem (1999) 1.48
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
Regulation of alternative replication bypass pathways at stalled replication forks and its effects on genome stability: a yeast model. Mutat Res (2003) 1.46
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res (2001) 1.45
Targeting DNA with triplexes. Curr Med Chem (2000) 1.44
Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res (1988) 1.41
Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J (1997) 1.41
Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. J Mol Biol (2001) 1.39
Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry (1999) 1.36
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol (2002) 1.33
Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem (1997) 1.32
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer (2001) 1.31
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol (2000) 1.31
Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol (1991) 1.29
Porphyrin binding to quadrupled T4G4. Biochemistry (1998) 1.29
DNA repeat expansions and human disease. Cell Mol Life Sci (2000) 1.26
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther (2003) 1.26
Differences and similarities between various tandem repeat sequences: minisatellites and microsatellites. Biochimie (1997) 1.25
Crystal structure of a four-stranded intercalated DNA: d(C4). Biochemistry (1994) 1.25
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst (2006) 1.79
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J (2007) 1.74
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther (2009) 1.66
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res (2007) 1.60
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
The catechol-O-methyltransferase (COMT) Val158Met polymorphism moderates the effect of antenatal stress on childhood behavioural problems: longitudinal evidence across multiple ages. Dev Med Child Neurol (2011) 1.42
Are two internal thoracic artery grafts as safe as one? Experience from Green Lane Hospital. N Z Med J (2012) 1.40
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem (2006) 1.39
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res (2009) 1.26
Influence of substituent modifications on DNA binding energetics of acridine-based anticancer agents. Biochemistry (2003) 1.24
Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons. Nucleic Acids Res (2002) 1.23
Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res (2012) 1.18
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res (2007) 1.17
Overview of mechanisms of cancer chemopreventive agents. Mutat Res (2005) 1.17
Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res (2007) 1.16
Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics (2011) 1.12
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J Med Chem (2003) 1.10
Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res (2003) 1.08
Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol (2007) 1.07
Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Org Biomol Chem (2008) 1.06
The Micronutrient Genomics Project: a community-driven knowledge base for micronutrient research. Genes Nutr (2010) 1.06
Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J Med Chem (2003) 1.05
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem (2011) 1.05
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem (2010) 1.04
In situ and in vitro antioxidant activity of sweetpotato anthocyanins. J Agric Food Chem (2004) 1.04
Obesity and diabetes genes are associated with being born small for gestational age: results from the Auckland Birthweight Collaborative study. BMC Med Genet (2010) 1.04
Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn's disease within New Zealand. Mutat Res (2009) 1.03
Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr (2011) 1.03
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol (2009) 1.03
Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc (2003) 1.02
Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline-quinones: inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis. Bioorg Med Chem (2008) 1.02
A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb) (2008) 1.02
Role of gut microbiota in Crohn's disease. Expert Rev Gastroenterol Hepatol (2009) 1.02
Production and characterisation of two wheat-bran fractions: an aleurone-rich and a pericarp-rich fraction. Mol Nutr Food Res (2005) 1.02
Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol (2013) 1.02
Alternative sources of omega-3 fats: can we find a sustainable substitute for fish? Nutrients (2013) 1.01
Substituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: chemistry, cytotoxicity and DNA sequence selectivity. J Inorg Biochem (2010) 1.01
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J Med Chem (2006) 1.00
DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Dietary and medicinal antimutagens and anticarcinogens: molecular mechanisms and chemopreventive potential--highlights of a symposium. Mutat Res (2003) 0.99
Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients. Hum Genomics (2013) 0.98
Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat Res (2007) 0.98
Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Hum Immunol (2009) 0.97
Beta-testing of PI3-kinase inhibitors: is beta better? Cancer Discov (2012) 0.97
Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine. Curr Pharmacogenomics Person Med (2011) 0.97
Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. J Med Chem (2002) 0.97
Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis (2011) 0.96
Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J Proteome Res (2010) 0.96
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res (2010) 0.96
Immunonutrition and cancer. Mutat Res (2004) 0.96
Interlaboratory validation of a CD71-based flow cytometric method (Microflow) for the scoring of micronucleated reticulocytes in mouse peripheral blood. Environ Mol Mutagen (2005) 0.95
Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorg Med Chem Lett (2005) 0.95
Kiwifruit promotes laxation in the elderly. Asia Pac J Clin Nutr (2002) 0.95
Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res (2009) 0.95
Dietary methyl donor deficiency during pregnancy in rats shapes learning and anxiety in offspring. Nutr Res (2011) 0.94
4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J Med Chem (2010) 0.94
Genetic variation in human disease and a new role for copy number variants. Mutat Res (2007) 0.94
Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase. J Am Chem Soc (2009) 0.93
Dietary fibres as "prebiotics": implications for colorectal cancer. Mol Nutr Food Res (2005) 0.93
Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets (2011) 0.93
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J Med Chem (2005) 0.93
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3. Eur J Med Chem (2013) 0.92
Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem (2007) 0.92
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res (2002) 0.92
The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol (2011) 0.91
Kiwifruit-based polyphenols and related antioxidants for functional foods: kiwifruit extract-enhanced gluten-free bread. Int J Food Sci Nutr (2009) 0.90
Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry (2012) 0.90
Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones. Bioorg Med Chem (2011) 0.90
Exploration of a series of 5-arylidene-2-thioxoimidazolidin-4-ones as inhibitors of the cytolytic protein perforin. J Med Chem (2013) 0.90
Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J Med Chem (2010) 0.89
Transcription factors as targets for DNA-interacting drugs. Curr Med Chem (2003) 0.89
Validation of inhibitors of an ABC transporter required to transport lipopolysaccharide to the cell surface in Escherichia coli. Bioorg Med Chem (2013) 0.88
Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res (2010) 0.88
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. Bioorg Med Chem (2007) 0.87
Prostate disease risk factors among a New Zealand cohort. J Nutrigenet Nutrigenomics (2013) 0.87
Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. Nutrients (2012) 0.87
Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res (2011) 0.87
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J Med Chem (2003) 0.87
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem (2007) 0.87
Antimalarial 9-anilinoacridine compounds directed at hematin. Antimicrob Agents Chemother (2003) 0.87
Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. Angew Chem Int Ed Engl (2011) 0.87
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3. J Med Chem (2012) 0.87
Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochem Pharmacol (2013) 0.87
Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. Org Biomol Chem (2005) 0.86
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J Med Chem (2007) 0.86
Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J Am Chem Soc (2004) 0.86
Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Am Chem Soc (2010) 0.85
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J Gastroenterol (2012) 0.85
Structure of 9-amino-[N-(2-dimethylamino)propyl]acridine-4-carboxamide bound to d(CGTACG)(2): a comparison of structures of d(CGTACG)(2) complexed with intercalatorsin the presence of cobalt. Acta Crystallogr D Biol Crystallogr (2004) 0.85